Tyrosine Kinase Inhibitors and Male Reproductive Health

Abstract

Tyrosine kinase inhibitors (TKIs) are a targeted class of cancer therapies effective against a range of malignancies and their use is growing significantly each year. Many men taking TKIs desire children, yet very little is known about the potential for reproductive harm of these medications. The mechanism of action of TKIs suggest a possible route to impairment of sperm functional properties or spermatogenesis.